News Breaks |
|
|
| November 28, 2012 |
| 08:30 EDT |  | CRIS, RHHBY | Curis licenses worldwide development, commercialization rights for IAP Inhibitor
Curis (CRIS) announced that it has licensed from Genentech, a member of the Roche Group, (RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins. Genentech has recently completed a Phase I clinical trial of GDC-0917, in which 42 people received daily oral doses of GDC-0917 for two weeks, followed by a one week rest period. This 21-day cycle is repeated until disease progression or study discontinuation for any other reason. The primary endpoints of the study include evaluating the safety and tolerability and the pharmacokinetics of GDC-0917 in people with solid tumors or lymphoma and determining the maximum-tolerated-dose and a potential recommended dose for further clinical studies. Secondary endpoints include a preliminary assessment of anti-tumor activity of GDC-0917 and evaluating pharmacodynamic markers. Genentech plans to present full study results at a medical conference in mid-2013, Curis said. |
|
|
News For CRIS;RHHBY From The Last 14 Days Check below for free stories on CRIS;RHHBY the last two weeks. |
|
|
| May 23, 2013 |
| 15:19 EDT |  | RHHBY | FDA announces approval of Roche diabetes test
 Subscribe for More Information |
|
| May 22, 2013 |
| 10:33 EDT | | RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:00 EDT |  | RHHBY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:02 EDT | | RHHBY | Roche upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | RHHBY | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | RHHBY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | RHHBY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| May 15, 2013 |
| 15:59 EDT | | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 12:13 EDT |  | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT | | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
| |
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| May 13, 2013 |
| 08:55 EDT | | RHHBY | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| 07:30 EDT | | RHHBY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| May 10, 2013 |
| 15:59 EDT | | RHHBY | Roche spokesman reiterates that Illumina is "off the table," Bloomberg reports
Subscribe for More Information |
|
| 11:48 EDT | | RHHBY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 07:04 EDT | | CRIS | Curis announces approval of Erivedge in Australia
Curis announced that Erivedge was approved for marketing registration by Australia's Therapeutic Goods Administration for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate. Erivedge is the first licensed treatment in Australia for patients with advanced basal cell carcinoma, a rare form of skin cancer which can be disfiguring, debilitating and even fatal. Curis earned a $4M milestone payment as a result of the TGA's approval of Erivedge and Curis is also entitled to receive royalties on Roche's future net sales of Erivedge in Australia. |
|
|
|
|
|
